FDA Warns Apotex Regarding Indian Drug Manufacturing Facility

According to The Wall Street Journal (2/4, Silverman, 5.67M) the US Food and Drug Administration sent a warning letter to Apotex, for violations in its manufacturing of generic medications at a facility in Bangalore, India. The FDA has sent several similar letters to Apotex in the past.

Share